Nantahala Capital Management LLC Invests $2.76 Million in Editas Medicine, Inc. $EDIT

Nantahala Capital Management LLC bought a new position in shares of Editas Medicine, Inc. (NASDAQ:EDIT) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 852,700 shares of the company’s stock, valued at approximately $2,762,748.

Several other institutional investors and hedge funds have also recently modified their holdings of EDIT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Editas Medicine by 122.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,600,000 shares of the company’s stock worth $3,016,000 after purchasing an additional 1,430,000 shares during the period. Acadian Asset Management LLC raised its position in Editas Medicine by 288.5% during the 1st quarter. Acadian Asset Management LLC now owns 752,162 shares of the company’s stock valued at $869,000 after purchasing an additional 558,567 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Editas Medicine by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,964,298 shares of the company’s stock worth $4,323,000 after buying an additional 20,521 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Editas Medicine by 15.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,065,722 shares of the company’s stock worth $2,345,000 after buying an additional 140,916 shares during the period. Finally, Bridgeway Capital Management LLC grew its position in shares of Editas Medicine by 500.0% during the 2nd quarter. Bridgeway Capital Management LLC now owns 120,000 shares of the company’s stock worth $264,000 after buying an additional 100,000 shares in the last quarter. Institutional investors own 71.90% of the company’s stock.

Insider Activity at Editas Medicine

In other news, CEO Gilmore Neil O’neill sold 15,380 shares of the stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $2.70, for a total value of $41,526.00. Following the sale, the chief executive officer owned 248,313 shares in the company, valued at $670,445.10. This represents a 5.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 21,503 shares of company stock valued at $57,910. 3.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

EDIT has been the subject of a number of research reports. Wall Street Zen raised shares of Editas Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. TD Cowen reissued a “buy” rating on shares of Editas Medicine in a research report on Wednesday, May 27th. LADENBURG THALM/SH SH initiated coverage on shares of Editas Medicine in a report on Tuesday, August 18th. They issued a “buy” rating and a $6.00 price target for the company. Weiss Ratings raised shares of Editas Medicine from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Chardan Capital increased their price objective on shares of Editas Medicine from $3.50 to $4.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Editas Medicine presently has an average rating of “Moderate Buy” and an average price target of $5.50.

More Editas Medicine News

Here are the key news stories impacting Editas Medicine this week:

• Positive Sentiment: Zacks raised its 2026 EPS forecast to a loss of $0.90 from a loss of $1.25, while increasing its 2027 forecast to a loss of $1.16 from $1.35 and its 2028 forecast to a loss of $1.34 from $1.37. The revisions suggest analysts expect Editas Medicine’s losses to be narrower than previously projected.
• Positive Sentiment: Quarterly estimates were also improved, including Q3 2026 EPS to a loss of $0.25 from $0.34, Q4 2026 to a loss of $0.24 from $0.33, Q1 2027 to a loss of $0.28 from $0.34, and Q2 2027 to a loss of $0.29 from $0.34. Zacks also raised its Q3 2027, Q4 2027, Q1 2028 and Q2 2028 forecasts.
• Neutral Sentiment: Despite the revisions, Editas is still expected to report losses in every listed period. The current-year consensus remains a loss of $0.85 per share, and the company’s negative earnings and cash-burn profile leave the stock highly dependent on clinical, regulatory and partnership developments.

Editas Medicine Trading Down 4.2%

Shares of Editas Medicine stock opened at $3.16 on Friday. The firm’s 50 day simple moving average is $3.00 and its two-hundred day simple moving average is $2.74. The firm has a market capitalization of $485.31 million, a price-to-earnings ratio of -4.21 and a beta of 2.14. Editas Medicine, Inc. has a 12-month low of $1.66 and a 12-month high of $4.54.

Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.12. Editas Medicine had a negative return on equity of 196.63% and a negative net margin of 157.32%.The company had revenue of $11.89 million during the quarter, compared to analysts’ expectations of $2.85 million. On average, sell-side analysts predict that Editas Medicine, Inc. will post -0.8 EPS for the current fiscal year.

Editas Medicine Company Profile

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.